As the Official Cancer Center of the State of New Mexico and as one of the nation's NCI-Designated Cancer Centers (2P30CA118100-09), the UNMCC has built collaborative partnerships with community oncologists and healthcare systems throughout the State of New Mexico to create the New Mexico Cancer Care Alliance (NMCCA), a joint 501c3 statewide cancer clinical trials organization and clinical research network. Through both these collaborative partnerships, UNMCC has worked to improve the quality of cancer care in our region; to enhance community-based cancer education, screening, and prevention; to promote community based participatory research; and to increase awareness, access and participation of all New Mexicans in NCl sponsored cancer screening, prevention and therapeutic clinical trials. The sites detailed herein which have worked together for 13 years to enroll New Mexico's highly diverse multiethnic and frequently underserved cancer patients on NCI Cooperative Group trials, as well as investigator initiated and industry trials; plan to continue this collaboration as the New Mexico NCI Community Oncology Research Program Minority/Underserved (NM NCORP). The NM NCORP has a catchment area for both the clinical trials program and the cancer care delivery research that includes the entire State. With a higher percentage of Hispanics and American Indians than any other state, New Mexico's 2.0 million citizens are 40.5% non-Hispanic White, 46.3% Hispanic, 9.4% American Indian, 2.1 % Black and the remainder is Asian & other ethnic minorities. New Mexicans experience unusual cancer patterns and tremendous cancer health disparities. New Mexico is ranked 43rd in the United States for per capita income. According to the 2011 Census Bureau 18.4% of New Mexicans live below the poverty level well above the national average of 13%. Over 50% of New Mexicans live in rural areas of the State with often limited access to healthcare and 22.9% of New Mexicans are uninsured (ranging from 4.8% to 31.6% among the different New Mexico counties). Of the patients accrued to cancer clinical trials at the UNMCC in 2012, 51% were racial/ethnic minorities (37.3% Hispanic/Latino, 8.2% American Indian, 2.1% African American, 1.1% Asian persons, 1.1% Native Hawaiians, and 1.1% reporting (two or more races) and 55% were women.

Public Health Relevance

Serving a vast geographic region of great beauty, with rich multicultural and multiethnic diversity, tremendous scientific opportunity, and challenging health and socioeconomic disparities, the NM NCORP is committed to making significant advances in cancer research and assuring access and participation in NCI-sponsored clinical trials to our regional communities.

National Institute of Health (NIH)
National Cancer Institute (NCI)
Clinical Research Cooperative Agreements - Single Project (UG1)
Project #
Application #
Study Section
Special Emphasis Panel (ZCA1-GRB-S (M1))
Program Officer
Mccaskill-Stevens, Worta J
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
University of New Mexico Health Sciences Center
Internal Medicine/Medicine
Schools of Medicine
United States
Zip Code
Henry, N Lynn; Unger, Joseph M; Schott, Anne F et al. (2018) Randomized, Multicenter, Placebo-Controlled Clinical Trial of Duloxetine Versus Placebo for Aromatase Inhibitor-Associated Arthralgias in Early-Stage Breast Cancer: SWOG S1202. J Clin Oncol 36:326-332
Hussain, Maha; Tangen, Catherine M; Thompson Jr, Ian M et al. (2018) Phase III Intergroup Trial of Adjuvant Androgen Deprivation With or Without Mitoxantrone Plus Prednisone in Patients With High-Risk Prostate Cancer After Radical Prostatectomy: SWOG S9921. J Clin Oncol 36:1498-1504
Yao, James C; Guthrie, Katherine A; Moran, Cesar et al. (2017) Phase III Prospective Randomized Comparison Trial of Depot Octreotide Plus Interferon Alfa-2b Versus Depot Octreotide Plus Bevacizumab in Patients With Advanced Carcinoid Tumors: SWOG S0518. J Clin Oncol 35:1695-1703
Carlos, Ruth C; Sicks, JoRean D; Chang, George J et al. (2017) Capacity for Cancer Care Delivery Research in National Cancer Institute Community Oncology Research Program Community Practices: Availability of Radiology and Primary Care Research Partners. J Am Coll Radiol 14:1530-1537
Sekeres, Mikkael A; Othus, Megan; List, Alan F et al. (2017) Randomized Phase II Study of Azacitidine Alone or in Combination With Lenalidomide or With Vorinostat in Higher-Risk Myelodysplastic Syndromes and Chronic Myelomonocytic Leukemia: North American Intergroup Study SWOG S1117. J Clin Oncol 35:2745-2753
Danilov, Alexey V; Li, Hongli; Press, Oliver W et al. (2017) Feasibility of interim positron emission tomography (PET)-adapted therapy in HIV-positive patients with advanced Hodgkin lymphoma (HL): a sub-analysis of SWOG S0816 Phase 2 trial. Leuk Lymphoma 58:461-465
Marur, Shanthi; Li, Shuli; Cmelak, Anthony J et al. (2017) E1308: Phase II Trial of Induction Chemotherapy Followed by Reduced-Dose Radiation and Weekly Cetuximab in Patients With HPV-Associated Resectable Squamous Cell Carcinoma of the Oropharynx- ECOG-ACRIN Cancer Research Group. J Clin Oncol 35:490-497
Heinrich, Michael C; Rankin, Cathryn; Blanke, Charles D et al. (2017) Correlation of Long-term Results of Imatinib in Advanced Gastrointestinal Stromal Tumors With Next-Generation Sequencing Results: Analysis of Phase 3 SWOG Intergroup Trial S0033. JAMA Oncol 3:944-952
Durie, Brian G M; Hoering, Antje; Abidi, Muneer H et al. (2017) Bortezomib with lenalidomide and dexamethasone versus lenalidomide and dexamethasone alone in patients with newly diagnosed myeloma without intent for immediate autologous stem-cell transplant (SWOG S0777): a randomised, open-label, phase 3 trial. Lancet 389:519-527
Achille, Nicholas J; Othus, Megan; Phelan, Kathleen et al. (2016) Association between early promoter-specific DNA methylation changes and outcome in older acute myeloid leukemia patients. Leuk Res 42:68-74

Showing the most recent 10 out of 13 publications